Biogen Idec, a biopharmaceutical company working mainly on multiple sclerosis drugs, has released its Q4 results.
Increased sales of its multiple sclerosis drugs has caused an increased earnings in the fourth quarter of 2011.
"Our success in 2011 gives us a strong position on
which to build," said George A.
Scangos, Ph.D., the company's chief executive officer. "In 2012 we
will focus on the continued growth and leadership of our marketed products and
the advancement of our strong pipeline. We will continue to work on risk
stratification to unlock the value of TYSABRI and we plan to launch the AVONEX
PEN in the US to support the continued growth of AVONEX. We are working to file
BG-12 as quickly as possible, and are preparing for the potential launch of the
product. We also anticipate phase III data later this year for our long-acting
factor VIII and factor IX in hemophilia, and dexpramipexole in ALS, and are
preparing for multiple filings and product launches where the data are
positive. At the same time we are working to strengthen our early stage
pipeline through internal research and strategic collaborations to build a
foundation for growth and innovation over the long term."
Further Reading:
SayPeople
